Philip Bonomi to Neoplasms
This is a "connection" page, showing publications Philip Bonomi has written about Neoplasms.
Connection Strength
0.479
-
Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med. 1998 Mar 15-Apr 15; 17(5-7):781-96.
Score: 0.130
-
Potential applications of apoptosis in modifying the biological behavior of therapeutically refractory cancers. Med Hypotheses. 1994 Oct; 43(4):207-13.
Score: 0.102
-
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16.
Score: 0.079
-
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004 May; 40(8):1193-8.
Score: 0.050
-
Does maximizing programmed cell death necessarily yield an optimum clinical advantage? Med Hypotheses. 1999 Mar; 52(3):235-8.
Score: 0.035
-
Inhibition of cancer cell proliferation by disruption of interdigitated/concatenated hierarchies of metabolic control/implementation processes: a proposal. Med Hypotheses. 1998 Feb; 50(2):119-23.
Score: 0.032
-
Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest. 1997; 15(4):358-68.
Score: 0.030
-
An interaction between type 1 and type 2 programmed cell death and clonogenic survival. Med Hypotheses. 2003 Nov-Dec; 61(5-6):583-5.
Score: 0.012
-
Free radical spin traps as adjuncts for the prevention and treatment of disease. Med Hypotheses. 1999 Jan; 52(1):53-7.
Score: 0.009